Table 1.
Demographic and clinical features of patients with panic disorder (PD) and healthy comparison subjects.
| Healthy Controls n=17 |
PD Patients* n=15 |
Significance | |
|---|---|---|---|
| Age (years) | 27.5 ± 8.6 | 21.7 ± 8.8 | p=0.079 |
| Sex (♂) | 10 | 4 | p=0.250 |
| χ2=1.321 | |||
| Race (white) | 15 (79%) | 15 (94%) | p=0.410 |
| χ2=0.678 | |||
| Body mass index (BMI) (kg/m2) | 26.3±5.7 | 30.69±12.5 | p=0.241 |
| Comorbidity | |||
| Generalized Anxiety Disorder | 0 | 12 | |
| Separation Anxiety Disorder | 0 | 0 | |
| Social Anxiety Disorder | 0 | 4 | |
| Agoraphobia | 0 | 7 | |
| Unspecified depressive disorder | 0 | 1 | |
| Persistent depressive disorder | 0 | 0 | |
| ADHD | 0 | 0 | |
| Substance use disorder, in remission | 0 | 1 | |
| History of major depressive disorder | 0 | 2 | |
| PDSS composite score | 0.04 ± 0.10 | 1.56 ± 0.81 | p<0.0001 |
| HAM-A score | 1.24 ± 1.52 | 21.87 ± 10.9 | p<0.0001 |
| QIDS score | 2.5 ± 2.4 | 16.87 ± 7.8 | p<0.0001 |
*
Among patients with PD who were receiving anxiety-related pharmacotherapy (n=9), treatment consisted of selective serotonin (norepinephrine) reuptake inhibitors (n=4), benzodiazepines (n=6 [one patient treated with an SSRI and an adjunctive benzodiazepine]), soporific medications (zolpidem, n=2) and an adjunctive second generation antipsychotic in one patient ([aripiprazole 2 mg q̄HS] n=1).